First‐line <scp>PD</scp>‐1/<scp>PD‐L1</scp> inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Zhai, Jinzhao; Lu, Jiangyue; Zhang, Zhibo; Wang, Yuan; Li, Xiaoyan; Zhang, Sujie; Mu, Shuai; Zhi, Xiaoyu; Ge, Xiangwei; Lu, Da-Yong; Hu, Yi; Wang, Jinliang

doi:10.1002/cam4.4589

Cited by 6 publications

(4 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 74 Several such studies have been performed in lung cancer, including evaluating safety and efficacy of bevacizumab biosimilars, 75 determining optimal platinum-based chemotherapy for early-stage resected NSCLC, 76 how smoking status influences effect of targeted therapy, 77 and choice of first-line treatment for patients on the basis of PD-L1 expression. 78 , 79 , 80 …”

Section: Treatmentmentioning

confidence: 99%

Integration of artificial intelligence in lung cancer: Rise of the machine

Ladbury¹,

Amini²,

Govindarajan³

et al. 2023

Cell Reports Medicine

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Integration of artificial intelligence in lung cancer: Rise of the machine

Ladbury¹,

Amini²,

Govindarajan³

et al. 2023

Cell Reports Medicine

View full text Add to dashboard Cite

“…Bevacizumab, as an inhibitor of vascular endothelial growth factor (VEGF), restrains growth of tumors by inhibiting angiogenesis, which is considered to contribute to the treatment of NSCLC ( 9 , 10 ). Notably, adjuvant bevacizumab plus platinum-based chemotherapy has provided certain clinical benefits in patients with NSCLC ( 11 , 12 ).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study

Jiang,

Rao,

Zhang

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

“…Frontline treatment options for patients with advanced or metastatic non–small cell lung cancer (NSCLC) have changed radically with the incorporation of immunotherapy into treatment algorithms . Immune checkpoint inhibitors targeting programmed cell death 1 protein (PD-1; eg, pembrolizumab and nivolumab), programmed cell death 1 ligand 1 (PD-L1; eg, atezolizumab), and cytotoxic T lymphocyte–associated antigen 4 (eg, ipilimumab), either as monotherapy or combined with chemotherapy, modify the tumor microenvironment and have emerged as a new standard of care for patients without actionable driver sequence variations . However, only a minority of tumors respond, and long-term survival for most patients remains poor.…”

Section: Introductionmentioning

confidence: 99%

“…1 Immune checkpoint inhibitors targeting programmed cell death 1 protein (PD-1; eg, pembrolizumab and nivolumab), programmed cell death 1 ligand 1 (PD-L1; eg, atezolizumab), and cytotoxic T lymphocyte-associated antigen 4 (eg, ipilimumab), either as monotherapy or combined with chemotherapy, modify the tumor microenvironment and have emerged as a new standard of care for patients without actionable driver sequence variations. [2][3][4][5][6][7][8][9] However, only a minority of tumors respond, and long-term survival for most patients remains poor. Atezolizumab has been approved as monotherapy for first-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (either ≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells) and no EGFR alteration or ALK translocation.…”

mentioning

confidence: 99%

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

et al. 2023

View full text Add to dashboard Cite

ImportanceAntiangiogenic drug combinations with anti–programmed cell death 1 protein and anti–programmed cell death 1 ligand 1 (PD-L1) agents are a novel treatment option for lung cancer. However, survival remains limited, and the activity of these combinations for tumors with high tumor mutation burden (TMB) is unknown.ObjectiveTo assess the clinical benefits and safety of atezolizumab plus bevacizumab for patients with high-TMB advanced nonsquamous non–small cell lung cancer (NSCLC).Design, Setting, and ParticipantsThis multicenter, single-arm, open-label, phase 2 nonrandomized controlled trial (Atezolizumab Plus Bevacizumab in First-Line NSCLC Patients [TELMA]) included treatment-naive patients aged 18 years or older with confirmed stage IIIB-IV nonsquamous NSCLC with TMB of 10 or more mutations/megabase and no EGFR, ALK, STK11, MDM2, or ROS1 alterations. From May 2019 through January 2021, patients were assessed at 13 sites in Spain, with follow-up until February 28, 2022.InterventionsParticipants were given atezolizumab, 1200 mg, plus bevacizumab, 15 mg/kg, on day 1 of each 21-day cycle. Treatment was continued until documented disease progression, unacceptable toxic effects, patient withdrawal, investigator decision, or death.Main Outcomes and MeasuresThe primary end point was 12-month progression-free survival (PFS) rate (according to Response Evaluation Criteria in Solid Tumours, version 1.1 criteria); PFS was defined as the time from enrollment to disease progression or death. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.ResultsA total of 307 patients were assessed for trial eligibility, of whom 266 were ineligible for enrollment. Of the 41 patients enrolled, 3 did not fulfill all inclusion criteria and were excluded. The remaining 38 patients (28 [73.7%] male; mean [SD] age, 63.7 [8.3] years) constituted the per-protocol population. The 12-month PFS rate was 51.3% (95% CI, 34.2%-66.0%), which met the primary end point. The 12-month overall survival (OS) rate was 72.0% (95% CI, 54.1%-83.9%). The median PFS was 13.0 months (95% CI, 7.9-18.0 months), and the median OS was not reached. Of the 38 patients, 16 (42.1%) achieved an objective response and 30 (78.9%) achieved disease control. The median time to response was 2.8 months (IQR, 2.8-3.58 months), with a median duration of response of 11.7 months (range, 3.57-22.4 months; the response was ongoing at cutoff). Of 16 responses, 8 (50.0%) were ongoing. Most adverse events were grade 1 or 2. For atezolizumab, the most common adverse events were fatigue (6 [15.8%]) and pruritus (6 [15.8%]). For bevacizumab, they were hypertension (10 [26.3%]) and proteinuria (4 [10.5%]). Drug discontinuation occurred in 2 patients receiving atezolizumab (5.3%) and 3 patients receiving bevacizumab (7.9%). PD-L1 levels were not associated with response, PFS, or OS.Conclusions and RelevanceThese findings suggest that atezolizumab with bevacizumab is a potential treatment for high-TMB nonsquamous NSCLC.Trial RegistrationClinicalTrials.gov Identifier: NCT03836066

show abstract

First‐line PD‐1/PD‐L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non‐squamous non‐small cell lung cancer: A Bayesian network meta‐analysis of randomized controlled trials

Cited by 6 publications

References 70 publications

Integration of artificial intelligence in lung cancer: Rise of the machine

Integration of artificial intelligence in lung cancer: Rise of the machine

Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

Contact Info

Product

Resources

About